Gabather
0,678
SEK
+35,6 %
GABA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
+35,6%
+4,63%
-7,12%
-54,58%
-50,07%
-69,39%
-82,87%
-83,36%
-95,74%
www.gabather.com
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GABA
Daglig lav / høj pris
0,678 / 0,698
SEK
Markedsværdi
16,08 mio. SEK
Aktieomsætning
413,11 SEK
Volumen
603
Finanskalender
Delårsrapport
28.11.2024
Årsrapport
27.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 12,6 % | 12,6 % |
| Nordnet Pension | 2,2 % | 2,2 % |
| Investment Aktiebolaget Balticum | 2,1 % | 2,1 % |
| Thomas Nilsson | 1,6 % | 1,6 % |
| Jorgen Jutholm | 1,5 % | 1,5 % |
| Handelsbanken Liv Försäkringsaktiebolag | 1,3 % | 1,3 % |
| Magnus Esselmark | 1,3 % | 1,3 % |
| Kristian Falk | 1,2 % | 1,2 % |
| Anders Asplund | 1,1 % | 1,1 % |
| Anica Kabbenas | 1,1 % | 1,1 % |
ViserAlle indholdstyper
Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools